No Data
No Data
No Data
No Data
No Data
Radiopharm Theranostics Advances Cancer Treatment With RAD 301 and RAD 302 Developments
Radiopharm Theranostics (ASX: RAD) has welcomed the release of new data identifying a promising pathway for its innovative RAD 301 and RAD 302 oncology developments.
Small CapsMar 15 09:14
Radiopharm Theranostics to Present Multiple Data Releases for RAD 301 at European Molecular Imaging Meeting
Radiopharm Theranostics Ltd (ASX:RAD, OTC:RDPTF) will present multiple data sets on its 68Ga-Trivehexin (RAD 301) technology during the European Molecular Imaging Meeting (EMIM) from March 12-15, 2024, in Porto, Portugal.
Investing.com Mar 6 09:24
Radiopharm Theranostics Doses First Patient in Pancreatic Cancer Imaging Study
Radiopharm Theranostics (ASX:RAD) dosed the first patient in a Phase 1 clinical trial investigating the safety and imaging profile of the radiopharmaceutical drug RAD 301, the radiotherapeutics firm s
MT NewswiresFeb 29 14:15
Radiopharm Theranostics Doses First Patient in RAD 301 Pancreatic Cancer Study
Biotechnology company Radiopharm Theranostics (ASX: RAD) has dosed the first patient in a Phase 1 study assessing the safety, dosimetry and imaging characteristics of the RAD 301 isotope in the treatment of advanced pancreatic cancer.
Small CapsFeb 29 07:40
Radiopharm Theranostics Set to Revolutionise Prostate Cancer Treatment With Terbium-161
A recent medical publication into prostate cancer has validated the development by clinical-stage biotech Radiopharm Theranostics (ASX: RAD) of its first-in-class Terbium-161 (Tb-161).
Small CapsFeb 28 11:00
Radiopharm Theranostics Has Terbium-161 Radiotherapeutics Validated by Pilot Study in Prostate Cancer
Radiopharm Theranostics Ltd (ASX:RAD, OTC:RDPTF) has highlighted a head-to-head pilot study in prostate cancer which validates its development of first-in-class Terbium-161 radiotherapeutics.
Investing.com Feb 28 09:35
No Data
No Data